Transaction DateRecipientSharesTypePriceValue
24th September 2020Louis Manzo8,299Exercise of derivative$3.70$30,706.30
27th July 2020Linda Marban41,497Exercise of derivative$3.70$153,538.90
27th July 2020Linda Marban15,652Payment by withholding$9.81$153,546.12
17th December 2019Louis Manzo20,391Grant/award etc.$0.00
17th December 2019David B Musket20,391Grant/award etc.$0.00
17th December 2019Frank Litvack20,391Grant/award etc.$0.00
Capricor Therapeutics
Capricor Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.

Ticker: CAPR
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1133869
Employees: 22
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags